The GLP-1 Megaguide (2025): Ozempic vs. Wegovy vs. Zepbound—and the Rest
TL;DR (Quick Comparison)
- Ozempic® (semaglutide injection): FDA-approved for type 2 diabetes; notable weight loss as a secondary effect. Weekly injection. Boxed warning for thyroid C-cell tumors, contraindicated with personal/family history of MTC or MEN2. FDA Access Data
- Wegovy® (semaglutide injection, 2.4 mg): FDA-approved for chronic weight management and (since March 8, 2024) to reduce risk of major cardiovascular events in adults with obesity/overweight and established CVD. Weekly injection; standard 5-step dose escalation. Same boxed warning. FDA Access Data+1
- Zepbound® (tirzepatide injection): FDA-approved for chronic weight management; delivers industry-leading average weight loss in trials. Weekly injection with gradual titration; same boxed warning. FDA Access Data+1
- Mounjaro® (tirzepatide): FDA-approved for type 2 diabetes; same active molecule as Zepbound, different indication and doses. Weekly injection; boxed warning applies. FDA Access Data
- Other GLP-1s / Incretin options: Saxenda® (liraglutide, daily) for weight management; Trulicity® (dulaglutide), Rybelsus® (oral semaglutide), Victoza® (liraglutide), Byetta®/Bydureon® (exenatide) primarily for type 2 diabetes. All carry the same class boxed warning/contraindication language. FDA Access Data+3FDA Access Data+3FDA Access Data+3
What are GLP-1 and “twincretins” (GIP/GLP-1)?
- GLP-1 receptor agonists mimic a gut hormone that helps regulate insulin, slows gastric emptying, reduces appetite, and supports weight loss.
- Tirzepatide (Zepbound/Mounjaro) is a dual GIP/GLP-1 receptor agonist (“twincretin”) that can drive larger average weight loss vs. GLP-1 alone in obesity trials. New England Journal of Medicine
Indications & Approvals (What each drug is officially for)
| Medicine | Generic | Class | FDA-Approved Indication(s) |
|---|---|---|---|
| Ozempic | Semaglutide (inj.) | GLP-1 RA | Type 2 diabetes glycemic control; reduces risk of CV events in T2D with CVD (per class data/label). Not approved for weight loss. Boxed warning. FDA Access Data |
| Wegovy | Semaglutide (inj.) 2.4 mg | GLP-1 RA | Chronic weight management in adults/adolescents (criteria apply) and reduction of MACE (CV death, MI, stroke) in adults with obesity/overweight and established CVD (Mar 8, 2024). Boxed warning. FDA Access Data+1 |
| Zepbound | Tirzepatide (inj.) | Dual GIP/GLP-1 | Chronic weight management in adults with obesity/overweight with comorbidity; boxed warning. FDA Access Data |
| Mounjaro | Tirzepatide (inj.) | Dual GIP/GLP-1 | Type 2 diabetes glycemic control; boxed warning. FDA Access Data |
| Saxenda | Liraglutide (inj.) | GLP-1 RA | Chronic weight management (daily injection); boxed warning. FDA Access Data |
| Trulicity | Dulaglutide (inj.) | GLP-1 RA | Type 2 diabetes; boxed warning. FDA Access Data |
| Rybelsus | Semaglutide (oral) | GLP-1 RA | Type 2 diabetes (oral tablet); boxed warning. (Obesity indication for oral sema pending at time of writing.) FDA Access Data |
Boxed warning & contraindication across this class: risk of thyroid C-cell tumors observed in rodents; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2. FDA Access Data+6FDA Access Data+6FDA Access Data+6
How well do they work? (Weight, A1c, and Heart Outcomes)
Weight loss (obesity/overweight without diabetes)
- Wegovy (semaglutide 2.4 mg): ~15% mean weight loss at 68 weeks (STEP-1, vs ~2–3% placebo), with durable ~15% at 2 years in extended analyses. PubMed+1
- Zepbound (tirzepatide): ~21% mean weight loss at 72 weeks at top doses (SURMOUNT-1), with half of patients achieving ≥20% loss; longer-term data show ~19% loss at 3 years after modest regain. Financial Times+2PubMed+2
- Head-to-head (2025 NEJM): Tirzepatide produced ~20.2% weight loss vs semaglutide’s lower result in adults with obesity without diabetes; exploratory ≥30% loss in ~19.7% on tirzepatide. New England Journal of Medicine+1
Glycemic control (type 2 diabetes)
- Ozempic (semaglutide inj.) and Rybelsus (oral sema) significantly lower A1c and weight; weekly or oral routes differ. Label-based usage depends on T2D treatment plan. FDA Access Data+1
- Mounjaro (tirzepatide) can deliver very strong A1c reductions alongside weight loss in T2D, reflected in its approval and trial program (SURPASS family; see label). FDA Access Data
Cardiovascular outcomes
- Wegovy (semaglutide 2.4 mg): In SELECT (obesity/overweight without diabetes but with established CVD), semaglutide reduced MACE by 20% (HR 0.80). This led to the first FDA approval for reducing CV risk in this population (Mar 8, 2024). New England Journal of Medicine+2PubMed+2
Dosing & Titration (What a typical schedule looks like)
Always follow your prescriber’s plan and the FDA label. Below are label-based overviews:
- Ozempic (semaglutide inj., weekly): start 0.25 mg weekly, then 0.5 mg, may increase to 1 mg and 2 mg for glycemic control. Not indicated for weight loss. FDA Access Data
- Wegovy (semaglutide 2.4 mg, weekly): 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg at ~4-week intervals as tolerated. FDA Access Data
- Zepbound (tirzepatide, weekly): 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg over 4-week steps as tolerated. FDA Access Data
- Mounjaro (tirzepatide, weekly): similar step-up for T2D (dose range differs by response/tolerability). FDA Access Data
- Saxenda (liraglutide, daily): daily titration to 3.0 mg for weight management. FDA Access Data
Pro-tips to discuss with your clinician: slow down titration if nausea is an issue; take on the same day each week; consider smaller/fatty meals and hydration during escalation.
Safety, Side Effects & Warnings
Common: nausea, vomiting, diarrhea/constipation, abdominal pain; typically most pronounced during dose increases. FDA Access Data+2FDA Access Data+2
Serious but less common (class):
- Thyroid C-cell tumor risk (boxed warning)—do not use with personal/family history of MTC or MEN2. FDA Access Data+2FDA Access Data+2
- Pancreatitis, gallbladder disease, acute kidney injury, and GI complications—seek urgent care for severe abdominal pain, persistent vomiting, or signs of dehydration. See labels. FDA Access Data+1
- Gastroparesis/ileus discussions: FDA has monitored GLP-1 safety signals; clinicians may pause therapy around anesthesia or procedures requiring empty stomach. U.S. Food and Drug Administration
Pregnancy & fertility: not recommended during pregnancy; discuss family planning. (See each label’s pregnancy/lactation section.) FDA Access Data+1
Counterfeits & compounded products: Regulatory actions and alerts have warned against fake or knockoff incretin products and certain compounded copies; stick to FDA-approved sources and licensed pharmacies. The Times+1
Who’s a Candidate? (Label-based criteria to discuss with your clinician)
- Weight management indications (e.g., Wegovy, Zepbound, Saxenda): generally BMI ≥30 or ≥27 with a weight-related condition (hypertension, dyslipidemia, OSA, etc.). See individual labels for full criteria and pediatric use. FDA Access Data+2FDA Access Data+2
- Type 2 diabetes: multiple GLP-1s and tirzepatide (Mounjaro) are approved; choice depends on A1c target, comorbidities, weight goals, CV risk, and insurance. FDA Access Data+1
- Established CVD without diabetes: Wegovy has the specific FDA approval for MACE risk reduction in adults with obesity/overweight and established CVD. U.S. Food and Drug Administration
How to Choose: Decision Guide
If your primary goal is…
- Maximum average weight loss: Zepbound (tirzepatide) often shows the highest mean loss in obesity trials; Wegovy follows closely; head-to-head data favor tirzepatide. Weigh efficacy vs. tolerability, insurance, and access. New England Journal of Medicine+2Financial Times+2
- Cardiovascular risk reduction (no diabetes): Wegovy is the only one with an FDA-cleared claim for reducing MACE in this specific population. U.S. Food and Drug Administration
- Oral route (type 2 diabetes): Rybelsus (oral semaglutide) avoids injections (note fasting administration rules). Oral obesity indications are in late-stage development but not yet approved in the U.S. as of Sept 24, 2025. FDA Access Data+1
- Daily vs weekly: Saxenda is daily; most others are weekly. Weekly is often preferred for convenience. FDA Access Data
Practical Use: What Patients Often Ask
1) How fast will I see results?
- Many notice appetite changes in the first few weeks at low doses; weight change typically accelerates during titration and continues for 12–18+ months with lifestyle support. Long-term data show sustained loss with some regain. Nature+1
2) What if I can’t tolerate the next step up?
- Work with your clinician to extend a dose step or pause escalation; manage GI effects with smaller meals, adequate protein/fiber, and hydration. (Label-consistent general strategies.) FDA Access Data
3) Do I have to stay on it forever?
- Obesity is chronic; discontinuation often leads to partial weight regain. Long-term planning (nutrition, activity, sleep, behavior, and in some cases continued pharmacotherapy) supports maintenance. Nature
4) Can I take these with other meds?
- Many combinations are common (e.g., with metformin in T2D), but avoid stacking incretin therapies. Always review meds for hypoglycemia risk (e.g., with insulin/sulfonylureas). See labels. FDA Access Data+1
Cost, Coverage & Access (High-level)
- Coverage varies widely by plan and indication (weight management vs diabetes). Some payers apply step therapy or BMI/comorbidity criteria for obesity meds; diabetes indications are often covered more broadly. (Check your insurer’s policy for GLP-1/GIP-GLP-1 agents.) A July 2025 state payer policy overview lists the major agents by category. Washington State Health Care Authority
- Be cautious with “compounded” or offshore sources; regulators have pushed back on non-approved copycats as shortages ease. AP News
Lifestyle & Clinical “Stacking” (Evidence-aligned)
- Nutrition: prioritize protein (satiety/lean mass), fiber, and whole foods; avoid large, greasy meals during titration to reduce nausea.
- Resistance training: helps preserve lean mass while losing fat.
- Sleep & stress: modulate appetite hormones and compliance.
- Medical add-ons (clinician-guided): antihypertensives/lipids optimization; OSA treatment; consider adjuncts based on labs (e.g., vitamin D, iron if indicated).
Advanced Corner: Trials & What’s Next
- SELECT (Wegovy): 17,604 participants; HR 0.80 for MACE reduction in adults with obesity/overweight and established CVD, no diabetes. PubMed+1
- SURMOUNT-1 (Zepbound): Up to ~21–23% average loss at higher doses; ≥20% loss in ~50–57% of patients; durable results with small regain at year 3. PubMed+2Financial Times+2
- Head-to-head (2025): Tirzepatide > semaglutide for % weight loss at 72 weeks in adults with obesity (no diabetes). New England Journal of Medicine
- Oral incretins: Oral semaglutide (for obesity) under FDA review; Lilly’s orforglipron reported stronger A1c/weight loss vs Rybelsus in T2D, highlighting a coming oral wave. (Not yet FDA-approved for obesity as of this writing.) Investors+1
Red-Flag Situations (Call your clinician promptly)
- Severe, persistent abdominal pain (with/without vomiting) → pancreatitis evaluation.
- Symptoms of gallstones (RUQ pain, fever, jaundice).
- Signs of dehydration (hypotension, low urine); kidney disease history requires close monitoring.
- Possible allergic reactions (rash, swelling, breathing difficulty).
See each product’s Warnings/Precautions. FDA Access Data+1
FAQs (SEO-friendly)
Q: Ozempic vs. Wegovy—what’s the difference?
A: Same active molecule (semaglutide), different indications and doses. Ozempic is for T2D (0.25→2 mg); Wegovy is 2.4 mg for chronic weight management and now CV risk reduction in adults with obesity/overweight and established CVD. FDA Access Data+2FDA Access Data+2
Q: Zepbound vs. Mounjaro—what’s the difference?
A: Same active (tirzepatide). Mounjaro is the T2D brand; Zepbound is the obesity brand/dosing for chronic weight management. FDA Access Data+1
Q: Which loses more weight—semaglutide or tirzepatide?
A: Head-to-head and separate trials suggest tirzepatide yields greater average loss at approved doses, but individual response varies and tolerability/coverage matter. New England Journal of Medicine+1
Q: Are these “forever” meds?
A: Obesity is chronic; stopping often leads to partial regain. Long-term plans (nutrition, activity, behavior)—and sometimes continued therapy—support maintenance. Nature
Q: Are there pills for weight loss yet?
A: As of Sept 24, 2025, no FDA-approved oral GLP-1 for obesity in the U.S., though oral semaglutide for obesity is in review and other oral incretins are in late trials. Investors
Q: How do I avoid fake or unsafe products?
A: Use licensed U.S. pharmacies; beware online “compounded” copies and counterfeits flagged by regulators and WHO; verify NDCs and packaging. AP News+1
On-Label vs. Off-Label
- Using Ozempic for weight loss in people without T2D is off-label; clinicians may favor Wegovy or Zepbound for on-label obesity treatment and coverage. Always follow FDA-approved labeling and your clinician’s guidance. FDA Access Data+1
The Full Roster: Major Incretin Medicines (2025)
- GLP-1 RAs (injectable): semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), lixisenatide (Adlyxin). FDA Access Data+1
- GLP-1 RA (oral): semaglutide (Rybelsus) for T2D (fasting administration). FDA Access Data
- Dual GIP/GLP-1: tirzepatide (Mounjaro for T2D, Zepbound for obesity). FDA Access Data+1
Implementation Blueprint (With Your Clinician)
- Assess eligibility & risks (BMI/comorbidities, CVD status, diabetes, thyroid/MEN2 history).
- Select agent & route (weekly vs daily vs oral, on-label indication).
- Plan titration and GI-friendly strategies.
- Lifestyle alignment (protein targets, training, sleep).
- Monitoring (weight, waist, A1c/fasting glucose as applicable, lipids, BP, labs if indicated).
- Long-term strategy (maintenance, dose adjustments, address plateaus, consider OSA/NAFLD care). Recent trials show semaglutide benefits in MASH (formerly NASH) endpoints under investigation. New England Journal of Medicine
Key Studies & Labels (Starter Reading List)
- Labels: Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Trulicity, Rybelsus. FDA Access Data+6FDA Access Data+6FDA Access Data+6
- SELECT (semaglutide): MACE reduction in obesity without diabetes; FDA CV-risk indication for Wegovy. New England Journal of Medicine+1
- STEP-1 (semaglutide 2.4 mg): ~15% weight loss at 68 weeks; durable at 2 years. PubMed+1
- SURMOUNT-1 (tirzepatide): ~21% mean weight loss at 72 weeks; strong long-term outcomes. PubMed+1
- Head-to-head (2025 NEJM): tirzepatide vs semaglutide in obesity (no diabetes)
